BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach

Withdrawn before enrolling

Conditions studied: BK Virus Infection, BK Virus Nephropathy

In brief

The investigator's aim in this study is to evaluate the impact of a new standard of care protocol for the treatment of BK viremia and nephropathy (BKVAN), which includes switching from Tacrolimus to equivalent dose of Cyclosporine in patients who have been diagnosed with BK viremia or BKVAN based on their viral load, overall graft function (estimated glomerular filtration rate), acute rejection, and rate of graft loss due to rejection or BKVAN.

Key facts

Study ID

NCT02758288

Run by

Loma Linda University

People needed

0

Starts

2015-09-01

Expected to finish

2022-07-01

Last updated by the study team

2020-10-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Recipient of kidney or combined kidney and pancreas
• BK viremia confirmed with blood PCR test with viral load over 500
• BK virus nephropathy confirmed by kidney biopsy

You may not qualify if…

• Recipient of combined organ transplant except kidney and pancreases
• Patient age < 18 years
• If patient does not consent for kidney biopsy
• Currently on treatment for acute rejection
• Patients with HIV, Hep C or Hep B infection
• Patients who are on other immunosuppression beside our standard regimen which includes Prograf, cellcept / Myfortic and prednisone

Where it is running

• Loma Linda University Medical Center — Loma Linda, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.